HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Cilta-Cel's Efficacy in Heavily Pretreated Patients With Multiple Myeloma: Thomas G. Martin, MD

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from the CARTITUDE-1 study presented at ASH 2021.

“In my mind, these [data from CARTITUDE-1] were the best results that have ever been shown in this truly triple-class refractory, 6 prior lines of therapy population. This is the most aggressive and the most responsive and efficacious therapy, as a single agent in refractory multiple myeloma treatment, that we've ever seen.”

Ciltacabtagene autoleucel (cilta-cel) produced deep and durable responses in heavily-pretreated patients with multiple myeloma, according to data from the phase 1/2 CARTITUDE-1 study (NCT03548207) presented at the 63rd Annual American Society of Hematology (ASH) Meeting, December 11-14, 2021, by Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California San Francisco, and co-leader, Cancer Immunology & Immunotherapy Program, Helen Diller Family Comprehensive Cancer Center.1,2

Investigators found that the 97 participants treated with cilta-celin the CARTITUDE-1 study had an overall response rate of 98% and that of 61 evaluable participants with minimal residual disease, the progression-free survival rate at 2 years was 100%. Also presented at ASH 2021 were positive results in a less-pretreated population.3

GeneTherapyLive spoke with Martin to learn more about the data from CARTITUDE-1 presented at ASH 2021. He discussed the positive results and cilta-cel's potential in this population.

REFERENCES
1. New data from CARTITUDE-1 Study show continued deep and durable responses of ciltacabtageneautoleucel (cilta-cel) in treatment of heavily pretreated patients with multiple myeloma. News release. Janssen. December 12, 2021. https://www.janssen.com/new-data-cartitude-1-study-show-continued-deep-and-durable-responses-ciltacabtagene-autoleucel-cilta
2. Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: Phase 1b/2 study of CiltacabtageneAutoleucel, a B-cell maturation antigen–Directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Presented at: 63rd Annual ASH Meeting; December 11-14, 2021, Atlanta, GA. Abstract 549.
3. Jakubowiak A, Usmani SZ, Berdeja JG, et al. Efficacy and safety of ciltacabtageneautoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 subgroup analysis. Presented at: 63rd Annual ASH Meeting; December 11-14, 2021, Atlanta, GA. Abstract 3938.